-
1
-
-
34948816016
-
Should schizophrenia be treated as a neurocognitive disorder
-
Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007; 64: 1115-1122.
-
(2007)
Arch Gen Psychiatry
, vol.64
, pp. 1115-1122
-
-
Green, M.F.1
Nuechterlein, K.H.2
-
2
-
-
84885476983
-
The relevance of cognitive, clinical and premorbid variables in predicting functional outcome for individuals with first-episode psychosis: A 3 year longitudinal study
-
Ayesa-Arriola R, Rodriguez-Sanchez JM, Perez-Iglesias R, Gonzalez-Blanch C, Pardo-Garcia G, Tabares-Seisdedos R et al. The relevance of cognitive, clinical and premorbid variables in predicting functional outcome for individuals with first-episode psychosis: a 3 year longitudinal study. Psychiatry Res 2013; 209: 302-308.
-
(2013)
Psychiatry Res
, vol.209
, pp. 302-308
-
-
Ayesa-Arriola, R.1
Rodriguez-Sanchez, J.M.2
Perez-Iglesias, R.3
Gonzalez-Blanch, C.4
Pardo-Garcia, G.5
Tabares-Seisdedos, R.6
-
3
-
-
0028850552
-
Glutamate receptor dysfunction and schizophrenia
-
Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
-
(1995)
Arch Gen Psychiatry
, vol.52
, pp. 998-1007
-
-
Olney, J.W.1
Farber, N.B.2
-
4
-
-
0030044715
-
The glutamatergic dysfunction hypothesis for schizophrenia
-
Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996; 3: 241-253.
-
(1996)
Harv Rev Psychiatry
, vol.3
, pp. 241-253
-
-
Coyle, J.T.1
-
5
-
-
0028323167
-
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
-
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
-
(1994)
Arch Gen Psychiatry
, vol.51
, pp. 199-214
-
-
Krystal, J.H.1
Karper, L.P.2
Seibyl, J.P.3
Freeman, G.K.4
Delaney, R.5
Bremner, J.D.6
-
6
-
-
0029927565
-
NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers
-
Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14: 301-307.
-
(1996)
Neuropsychopharmacology
, vol.14
, pp. 301-307
-
-
Malhotra, A.K.1
Pinals, D.A.2
Weingartner, H.3
Sirocco, K.4
Missar, C.D.5
Pickar, D.6
-
7
-
-
54049141721
-
Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection
-
Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008; 60: 358-403.
-
(2008)
Pharmacol Rev
, vol.60
, pp. 358-403
-
-
Lieberman, J.A.1
Bymaster, F.P.2
Meltzer, H.Y.3
Deutch, A.Y.4
Duncan, G.E.5
Marx, C.E.6
-
8
-
-
0030749913
-
Ketamineinduced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics
-
Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D et al. Ketamineinduced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17: 141-150.
-
(1997)
Neuropsychopharmacology
, vol.17
, pp. 141-150
-
-
Malhotra, A.K.1
Pinals, D.A.2
Adler, C.M.3
Elman, I.4
Clifton, A.5
Pickar, D.6
-
9
-
-
0033761169
-
Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia
-
Ibrahim HM, Hogg AJ Jr, Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry 2000; 157: 1811-1823.
-
(2000)
Am J Psychiatry
, vol.157
, pp. 1811-1823
-
-
Ibrahim, H.M.1
Hogg, A.J.2
Healy, D.J.3
Haroutunian, V.4
Davis, K.L.5
Meador-Woodruff, J.H.6
-
11
-
-
0033377681
-
Panmodal processing imprecision as a basis for dysfunction of transient memory storage systems in schizophrenia
-
Javitt DC, Liederman E, Cienfuegos A, Shelley AM. Panmodal processing imprecision as a basis for dysfunction of transient memory storage systems in schizophrenia. Schizophr Bull 1999; 25: 763-775.
-
(1999)
Schizophr Bull
, vol.25
, pp. 763-775
-
-
Javitt, D.C.1
Liederman, E.2
Cienfuegos, A.3
Shelley, A.M.4
-
12
-
-
0348047434
-
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: A retrospective analysis
-
Heresco-Levy U, Javitt DC. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 2004; 66: 89-96.
-
(2004)
Schizophr Res
, vol.66
, pp. 89-96
-
-
Heresco-Levy, U.1
Javitt, D.C.2
-
13
-
-
18844441253
-
Placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results
-
Diaz P, Bhaskara S, Dursun SM, Double-blind Deakin B. Placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. J Clin Psychopharmacol 2005; 25: 277-278.
-
(2005)
J Clin Psychopharmacol
, vol.25
, pp. 277-278
-
-
Diaz, P.1
Bhaskara, S.2
Dursun, S.M.3
Double-Blind Deakin, B.4
-
14
-
-
77955056793
-
High dose D-serine in the treatment of schizophrenia
-
Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 2010; 121: 125-130.
-
(2010)
Schizophr Res
, vol.121
, pp. 125-130
-
-
Kantrowitz, J.T.1
Malhotra, A.K.2
Cornblatt, B.3
Silipo, G.4
Balla, A.5
Suckow, R.F.6
-
15
-
-
84899052394
-
Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: A review of old and new targets
-
Ahmed AO, Bhat IA. Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets. CNS Drugs 2014; 28: 301-318.
-
(2014)
CNS Drugs
, vol.28
, pp. 301-318
-
-
Ahmed, A.O.1
Bhat, I.A.2
-
16
-
-
77953545879
-
A randomized, doubleblind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
-
Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, doubleblind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 2010; 13: 451-460.
-
(2010)
Int J Neuropsychopharmacol
, vol.13
, pp. 451-460
-
-
Lane, H.Y.1
Lin, C.H.2
Huang, Y.J.3
Liao, C.H.4
Chang, Y.C.5
Tsai, G.E.6
-
17
-
-
84890018607
-
Add-on treatment of benzoate for schizophrenia: A randomized, double-blind, placebo-controlled trial of D-Amino acid oxidase inhibitor
-
Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-Amino acid oxidase inhibitor. JAMA Psychiatry 2013; 70: 1267-1275.
-
(2013)
JAMA Psychiatry
, vol.70
, pp. 1267-1275
-
-
Lane, H.Y.1
Lin, C.H.2
Green, M.F.3
Hellemann, G.4
Huang, C.C.5
Chen, P.W.6
-
18
-
-
38149132338
-
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia
-
Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008; 33: 465-472.
-
(2008)
Neuropsychopharmacology
, vol.33
, pp. 465-472
-
-
Goff, D.C.1
Lamberti, J.S.2
Leon, A.C.3
Green, M.F.4
Miller, A.L.5
Patel, J.6
-
19
-
-
77949447469
-
Strategies to enhance N-methyl-D-Aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-Analysis
-
Tsai GE, Lin PY. Strategies to enhance N-methyl-D-Aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-Analysis. Curr Pharm Des 2010; 16: 522-537.
-
(2010)
Curr Pharm des
, vol.16
, pp. 522-537
-
-
Tsai, G.E.1
Lin, P.Y.2
-
20
-
-
84883472062
-
Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: Meta-Analytical investigation of efficacy
-
Choi KH, Wykes T, Kurtz MM. Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-Analytical investigation of efficacy. Br J Psychiatry 2013; 203: 172-178.
-
(2013)
Br J Psychiatry
, vol.203
, pp. 172-178
-
-
Choi, K.H.1
Wykes, T.2
Kurtz, M.M.3
-
21
-
-
42949123365
-
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
-
Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008; 7: 426-437.
-
(2008)
Nat Rev Drug Discov
, vol.7
, pp. 426-437
-
-
Sanacora, G.1
Zarate, C.A.2
Krystal, J.H.3
Manji, H.K.4
-
22
-
-
55049131112
-
Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors
-
Imbesi M, Uz T, Manev R, Sharma RP, Manev H. Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors. Neurosci Lett 2008; 447: 134-137.
-
(2008)
Neurosci Lett
, vol.447
, pp. 134-137
-
-
Imbesi, M.1
Uz, T.2
Manev, R.3
Sharma, R.P.4
Manev, H.5
-
23
-
-
0027380359
-
Presynaptic co-localization of carnosine and glutamate in olfactory neurones
-
Sassoe-Pognetto M, Cantino D, Panzanelli P, Verdun di Cantogno L, Giustetto M, Margolis FL et al. Presynaptic co-localization of carnosine and glutamate in olfactory neurones. Neuroreport 1993; 5: 7-10.
-
(1993)
Neuroreport
, vol.5
, pp. 7-10
-
-
Sassoe-Pognetto, M.1
Cantino, D.2
Panzanelli, P.3
Verdun Di Cantogno, L.4
Giustetto, M.5
Margolis, F.L.6
-
24
-
-
0030745226
-
Co-localization of carnosine and glutamate in photoreceptors and bipolar cells of the frog retina
-
Panzanelli P, Cantino D, Sassoe-Pognetto M. Co-localization of carnosine and glutamate in photoreceptors and bipolar cells of the frog retina. Brain Res 1997; 758: 143-152.
-
(1997)
Brain Res
, vol.758
, pp. 143-152
-
-
Panzanelli, P.1
Cantino, D.2
Sassoe-Pognetto, M.3
-
25
-
-
0032210918
-
Carnosine and beta-Alanine release is stimulated by glutamatergic receptors in cultured rat oligodendrocytes
-
Bakardjiev A. Carnosine and beta-Alanine release is stimulated by glutamatergic receptors in cultured rat oligodendrocytes. Glia 1998; 24: 346-351.
-
(1998)
Glia
, vol.24
, pp. 346-351
-
-
Bakardjiev, A.1
-
26
-
-
0032950897
-
Redox mechanisms at the glutamate synapse and their significance: A review
-
Smythies J. Redox mechanisms at the glutamate synapse and their significance: a review. Eur J Pharmacol 1999; 370: 1-7.
-
(1999)
Eur J Pharmacol
, vol.370
, pp. 1-7
-
-
Smythies, J.1
-
27
-
-
0032870428
-
Hydroxyl radical scavenging by carnosine and Cu(II)-carnosine complexes: A pulse-radiolysis and spectroscopic study
-
Tamba M, Torreggiani A. Hydroxyl radical scavenging by carnosine and Cu(II)-carnosine complexes: a pulse-radiolysis and spectroscopic study. Int J Radiat Biol 1999; 75: 1177-1188.
-
(1999)
Int J Radiat Biol
, vol.75
, pp. 1177-1188
-
-
Tamba, M.1
Torreggiani, A.2
-
28
-
-
84906228003
-
Targeting of NMDA receptors in new treatments for schizophrenia
-
Hashimoto K. Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin Ther Targets 2014; 18: 1049-1063.
-
(2014)
Expert Opin Ther Targets
, vol.18
, pp. 1049-1063
-
-
Hashimoto, K.1
-
29
-
-
67449123074
-
Proof-ofconcept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia
-
Marx CE, Keefe RS, Buchanan RW, Hamer RM, Kilts JD, Bradford DW et al. Proof-ofconcept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 2009; 34: 1885-1903.
-
(2009)
Neuropsychopharmacology
, vol.34
, pp. 1885-1903
-
-
Marx, C.E.1
Keefe, R.S.2
Buchanan, R.W.3
Hamer, R.M.4
Kilts, J.D.5
Bradford, D.W.6
-
30
-
-
84907469449
-
A role for picomolar concentrations of pregnenolone sulfate in synaptic activity-dependent Ca2 + signaling and CREB activation
-
Smith CC, Martin SC, Sugunan K, Russek SJ, Gibbs TT, Farb DH. A role for picomolar concentrations of pregnenolone sulfate in synaptic activity-dependent Ca2 + signaling and CREB activation. Mol Pharmacol 2014; 86: 390-398.
-
(2014)
Mol Pharmacol
, vol.86
, pp. 390-398
-
-
Smith, C.C.1
Martin, S.C.2
Sugunan, K.3
Russek, S.J.4
Gibbs, T.T.5
Farb, D.H.6
-
31
-
-
84925548115
-
Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement
-
Group P
-
Moher D, Liberati A, Tetzlaff J, Altman DG. Group P. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012.
-
(2009)
J Clin Epidemiol
, vol.62
, pp. 1006-1012
-
-
Moher, D.1
Liberati, A.2
Tetzlaff, J.3
Altman, D.G.4
-
32
-
-
4444220908
-
Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria
-
Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004; 56: 301-307.
-
(2004)
Biol Psychiatry
, vol.56
, pp. 301-307
-
-
Green, M.F.1
Nuechterlein, K.H.2
Gold, J.M.3
Barch, D.M.4
Cohen, J.5
Essock, S.6
-
34
-
-
0023921695
-
Effects of keto acid supplements on renal function and histology in azotemic rats fed high-protein diets
-
Hirschberg R, Cohen AH, Kopple JD. Effects of keto acid supplements on renal function and histology in azotemic rats fed high-protein diets. Am J Nephrol 1988; 8: 50-56.
-
(1988)
Am J Nephrol
, vol.8
, pp. 50-56
-
-
Hirschberg, R.1
Cohen, A.H.2
Kopple, J.D.3
-
36
-
-
0030922816
-
Bias in meta-Analysis detected by a simple, graphical test
-
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-Analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
-
(1997)
BMJ
, vol.315
, pp. 629-634
-
-
Egger, M.1
Davey Smith, G.2
Schneider, M.3
Minder, C.4
-
37
-
-
0033934949
-
Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-Analysis
-
Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-Analysis. Biometrics 2000; 56: 455-463.
-
(2000)
Biometrics
, vol.56
, pp. 455-463
-
-
Duval, S.1
Tweedie, R.2
-
38
-
-
79960201543
-
Effects of body position, imaging plane, and observer on computed tomographic measurements of the lumbosacral intervertebral foraminal area in dogs
-
Higgins BM, Cripps PJ, Baker M, Moore L, Penrose FE, McConnell JF. Effects of body position, imaging plane, and observer on computed tomographic measurements of the lumbosacral intervertebral foraminal area in dogs. Am J Vet Res 2011; 72: 905-917.
-
(2011)
Am J Vet Res
, vol.72
, pp. 905-917
-
-
Higgins, B.M.1
Cripps, P.J.2
Baker, M.3
Moore, L.4
Penrose, F.E.5
McConnell, J.F.6
-
39
-
-
84895782150
-
D-Cycloserine augmentation of cognitive remediation in schizophrenia
-
Cain CK, McCue M, Bello I, Creedon T, Tang DI, Laska E et al. d-Cycloserine augmentation of cognitive remediation in schizophrenia. Schizophr Res 2014; 153: 177-183.
-
(2014)
Schizophr Res
, vol.153
, pp. 177-183
-
-
Cain, C.K.1
McCue, M.2
Bello, I.3
Creedon, T.4
Tang, D.I.5
Laska, E.6
-
40
-
-
84895818899
-
Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial
-
Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res 2014; 153: 169-176.
-
(2014)
Schizophr Res
, vol.153
, pp. 169-176
-
-
Liu, F.1
Guo, X.2
Wu, R.3
Ou, J.4
Zheng, Y.5
Zhang, B.6
-
41
-
-
84896404591
-
The selective glycine uptake inhibitor Org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: Results from the GIANT trial
-
Schoemaker JH, Jansen WT, Schipper J, Szegedi A. The selective glycine uptake inhibitor Org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. Journal of Clinical Psychopharmacology 2014; 34: 190-198.
-
(2014)
Journal of Clinical Psychopharmacology
, vol.34
, pp. 190-198
-
-
Schoemaker, J.H.1
Jansen, W.T.2
Schipper, J.3
Szegedi, A.4
-
42
-
-
84872486732
-
Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: An international collaborative pilot study
-
D'Souza DC, Radhakrishnan R, Perry E, Bhakta S, Singh NM, Yadav R et al. Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. Neuropsychopharmacology 2013; 38: 492-503.
-
(2013)
Neuropsychopharmacology
, vol.38
, pp. 492-503
-
-
D'Souza, D.C.1
Radhakrishnan, R.2
Perry, E.3
Bhakta, S.4
Singh, N.M.5
Yadav, R.6
-
43
-
-
84869879025
-
A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia
-
Chengappa KN, Turkin SR, DeSanti S, Bowie CR, Brar JS, Schlicht PJ et al. A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia. Schizophr Res 2012; 142: 145-152.
-
(2012)
Schizophr Res
, vol.142
, pp. 145-152
-
-
Chengappa, K.N.1
Turkin, S.R.2
DeSanti, S.3
Bowie, C.R.4
Brar, J.S.5
Schlicht, P.J.6
-
44
-
-
84863550158
-
A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia
-
Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA et al. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry 2012; 73: e728-e734.
-
(2012)
J Clin Psychiatry
, vol.73
, pp. e728-e734
-
-
Weiser, M.1
Heresco-Levy, U.2
Davidson, M.3
Javitt, D.C.4
Werbeloff, N.5
Gershon, A.A.6
-
45
-
-
77649112679
-
A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia
-
Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71: 138-149.
-
(2010)
J Clin Psychiatry
, vol.71
, pp. 138-149
-
-
Levkovitz, Y.1
Mendlovich, S.2
Riwkes, S.3
Braw, Y.4
Levkovitch-Verbin, H.5
Gal, G.6
-
46
-
-
48749112603
-
N-Acetyl cysteine as a glutathione precursor for schizophrenia-A double-blind, randomized, placebocontrolled trial
-
Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I et al. N-Acetyl cysteine as a glutathione precursor for schizophrenia-A double-blind, randomized, placebocontrolled trial. Biol Psychiatry 2008; 64: 361-368.
-
(2008)
Biol Psychiatry
, vol.64
, pp. 361-368
-
-
Berk, M.1
Copolov, D.2
Dean, O.3
Lu, K.4
Jeavons, S.5
Schapkaitz, I.6
-
47
-
-
35748969317
-
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments
-
Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164: 1593-1602.
-
(2007)
Am J Psychiatry
, vol.164
, pp. 1593-1602
-
-
Buchanan, R.W.1
Javitt, D.C.2
Marder, S.R.3
Schooler, N.R.4
Gold, J.M.5
McMahon, R.P.6
-
48
-
-
4944233170
-
Effects of D-cycloserine on negative symptoms in schizophrenia
-
Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S et al. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res 2004; 71: 239-248.
-
(2004)
Schizophr Res
, vol.71
, pp. 239-248
-
-
Duncan, E.J.1
Szilagyi, S.2
Schwartz, M.P.3
Bugarski-Kirola, D.4
Kunzova, A.5
Negi, S.6
-
49
-
-
0034796599
-
A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia
-
Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001; 21: 484-487.
-
(2001)
J Clin Psychopharmacol
, vol.21
, pp. 484-487
-
-
Goff, D.C.1
Leahy, L.2
Berman, I.3
Posever, T.4
Herz, L.5
Leon, A.C.6
-
50
-
-
0032902238
-
A placebocontrolled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia
-
Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA et al. A placebocontrolled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56: 21-27.
-
(1999)
Arch Gen Psychiatry
, vol.56
, pp. 21-27
-
-
Goff, D.C.1
Tsai, G.2
Levitt, J.3
Amico, E.4
Manoach, D.5
Schoenfeld, D.A.6
-
51
-
-
0032700978
-
D-serine added to clozapine for the treatment of schizophrenia
-
Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999; 156: 1822-1825.
-
(1999)
Am J Psychiatry
, vol.156
, pp. 1822-1825
-
-
Tsai, G.E.1
Yang, P.2
Chung, L.C.3
Tsai, I.C.4
Tsai, C.W.5
Coyle, J.T.6
-
52
-
-
0032403626
-
D-serine added to antipsychotics for the treatment of schizophrenia
-
Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44: 1081-1089.
-
(1998)
Biol Psychiatry
, vol.44
, pp. 1081-1089
-
-
Tsai, G.1
Yang, P.2
Chung, L.C.3
Lange, N.4
Coyle, J.T.5
-
53
-
-
77952974468
-
International consensus study of antipsychotic dosing
-
Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686-693.
-
(2010)
Am J Psychiatry
, vol.167
, pp. 686-693
-
-
Gardner, D.M.1
Murphy, A.L.2
O'Donnell, H.3
Centorrino, F.4
Baldessarini, R.J.5
-
55
-
-
84868680041
-
No correlation between plasma NMDA-related glutamatergic amino acid levels and cognitive function in medicated patients with schizophrenia
-
Ohnuma T, Sakai Y, Maeshima H, Higa M, Hanzawa R, Kitazawa M et al. No correlation between plasma NMDA-related glutamatergic amino acid levels and cognitive function in medicated patients with schizophrenia. Int J Psychiatry Med 2012; 44: 17-27.
-
(2012)
Int J Psychiatry Med
, vol.44
, pp. 17-27
-
-
Ohnuma, T.1
Sakai, Y.2
Maeshima, H.3
Higa, M.4
Hanzawa, R.5
Kitazawa, M.6
-
56
-
-
78650034460
-
Glutamate as a marker of cognitive function in schizophrenia: A proton spectroscopic imaging study at 4 Tesla
-
Bustillo JR, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C et al. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry 2011; 69: 19-27.
-
(2011)
Biol Psychiatry
, vol.69
, pp. 19-27
-
-
Bustillo, J.R.1
Chen, H.2
Gasparovic, C.3
Mullins, P.4
Caprihan, A.5
Qualls, C.6
-
57
-
-
84860743254
-
Elevated prefrontal cortex gamma-Aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy
-
Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X et al. Elevated prefrontal cortex gamma-Aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2012; 69: 449-459.
-
(2012)
Arch Gen Psychiatry
, vol.69
, pp. 449-459
-
-
Kegeles, L.S.1
Mao, X.2
Stanford, A.D.3
Girgis, R.4
Ojeil, N.5
Xu, X.6
-
58
-
-
84890084726
-
Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia
-
Kraguljac NV, White DM, Reid MA, Lahti AC. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 2013; 70: 1294-1302.
-
(2013)
JAMA Psychiatry
, vol.70
, pp. 1294-1302
-
-
Kraguljac, N.V.1
White, D.M.2
Reid, M.A.3
Lahti, A.C.4
-
59
-
-
34047185227
-
Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: A proton magnetic resonance spectroscopy study
-
Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, Kersting A et al. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J Psychiatr Res 2007; 41: 625-634.
-
(2007)
J Psychiatr Res
, vol.41
, pp. 625-634
-
-
Ohrmann, P.1
Siegmund, A.2
Suslow, T.3
Pedersen, A.4
Spitzberg, K.5
Kersting, A.6
-
60
-
-
84878988768
-
Proton magnetic resonance spectroscopy of the + in schizophrenia
-
Reid MA, Kraguljac NV, Avsar KB, White DM, den Hollander JA, Lahti AC. Proton magnetic resonance spectroscopy of the + in schizophrenia. Schizophr Res 2013; 147: 348-354.
-
(2013)
Schizophr Res
, vol.147
, pp. 348-354
-
-
Reid, M.A.1
Kraguljac, N.V.2
Avsar, K.B.3
White, D.M.4
Den Hollander, J.A.5
Lahti, A.C.6
-
61
-
-
39049122010
-
Neurochemical and structural correlates of executive dysfunction in schizophrenia
-
Rusch N, Tebartz van Elst L, Valerius G, Buchert M, Thiel T, Ebert D et al. Neurochemical and structural correlates of executive dysfunction in schizophrenia. Schizophr Res 2008; 99: 155-163.
-
(2008)
Schizophr Res
, vol.99
, pp. 155-163
-
-
Rusch, N.1
Tebartz Van Elst, L.2
Valerius, G.3
Buchert, M.4
Thiel, T.5
Ebert, D.6
-
62
-
-
71849110853
-
Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: A preliminary study
-
Shirayama Y, Obata T, Matsuzawa D, Nonaka H, Kanazawa Y, Yoshitome E et al. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage 2010; 49: 2783-2790.
-
(2010)
Neuroimage
, vol.49
, pp. 2783-2790
-
-
Shirayama, Y.1
Obata, T.2
Matsuzawa, D.3
Nonaka, H.4
Kanazawa, Y.5
Yoshitome, E.6
-
63
-
-
84892847787
-
Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings
-
Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A et al. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res 2014; 152: 325-332.
-
(2014)
Schizophr Res
, vol.152
, pp. 325-332
-
-
Poels, E.M.1
Kegeles, L.S.2
Kantrowitz, J.T.3
Javitt, D.C.4
Lieberman, J.A.5
Abi-Dargham, A.6
-
64
-
-
14844321950
-
Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up
-
Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005; 162: 495-506.
-
(2005)
Am J Psychiatry
, vol.162
, pp. 495-506
-
-
Milev, P.1
Ho, B.C.2
Arndt, S.3
Andreasen, N.C.4
-
65
-
-
84895894183
-
Neurocognitive predictors of remission of symptoms and social and role functioning in the early course of first-episode schizophrenia
-
Torgalsboen AK, Mohn C, Rishovd Rund B. Neurocognitive predictors of remission of symptoms and social and role functioning in the early course of first-episode schizophrenia. Psychiatry Res 2014; 216: 1-5.
-
(2014)
Psychiatry Res
, vol.216
, pp. 1-5
-
-
Torgalsboen, A.K.1
Mohn, C.2
Rishovd Rund, B.3
-
66
-
-
84887009409
-
AMPARs and synaptic plasticity: The last 25 years
-
Huganir RL, Nicoll RA. AMPARs and synaptic plasticity: the last 25 years. Neuron 2013; 80: 704-717.
-
(2013)
Neuron
, vol.80
, pp. 704-717
-
-
Huganir, R.L.1
Nicoll, R.A.2
-
67
-
-
84929193210
-
Altered glutamate protein co-expression network topology linked to spine loss in the auditory cortex of schizophrenia
-
MacDonald ML, Ding Y, Newman J, Hemby S, Penzes P, Lewis DA et al. Altered glutamate protein co-expression network topology linked to spine loss in the auditory cortex of schizophrenia. Biol Psychiatry 2015; 77: 959-968.
-
(2015)
Biol Psychiatry
, vol.77
, pp. 959-968
-
-
MacDonald, M.L.1
Ding, Y.2
Newman, J.3
Hemby, S.4
Penzes, P.5
Lewis, D.A.6
-
68
-
-
36749009127
-
Mutations in ionotropic AMPA receptor 3 alter channel properties and are associated withmoderate cognitive impairment in humans
-
Wu Y, Arai AC, Rumbaugh G, Srivastava AK, Turner G, Hayashi T et al. Mutations in ionotropic AMPA receptor 3 alter channel properties and are associated withmoderate cognitive impairment in humans. Proc Natl Acad Sci USA 2007; 104: 18163-18168.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 18163-18168
-
-
Wu, Y.1
Arai, A.C.2
Rumbaugh, G.3
Srivastava, A.K.4
Turner, G.5
Hayashi, T.6
-
69
-
-
0029592136
-
NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia
-
Olney JW, Farber NB. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 1995; 13: 335-345.
-
(1995)
Neuropsychopharmacology
, vol.13
, pp. 335-345
-
-
Olney, J.W.1
Farber, N.B.2
-
70
-
-
0042343859
-
Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine
-
Takahata R, Moghaddam B. Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 2003; 28: 1117-1124.
-
(2003)
Neuropsychopharmacology
, vol.28
, pp. 1117-1124
-
-
Takahata, R.1
Moghaddam, B.2
-
71
-
-
0030900732
-
Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
-
Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-2927.
-
(1997)
J Neurosci
, vol.17
, pp. 2921-2927
-
-
Moghaddam, B.1
Adams, B.2
Verma, A.3
Daly, D.4
-
72
-
-
2942537881
-
NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex
-
Jackson ME, Homayoun H, Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA 2004; 101: 8467-8472.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 8467-8472
-
-
Jackson, M.E.1
Homayoun, H.2
Moghaddam, B.3
-
73
-
-
84881313914
-
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
-
Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 2013; 263: 367-377.
-
(2013)
Eur Arch Psychiatry Clin Neurosci
, vol.263
, pp. 367-377
-
-
Hashimoto, K.1
Malchow, B.2
Falkai, P.3
Schmitt, A.4
-
74
-
-
0016682243
-
D-serine nephrotoxicity. The nature of proteinuria, glucosuria, and aminoaciduria in acute tubular necrosis
-
Carone FA, Ganote CE. D-serine nephrotoxicity. The nature of proteinuria, glucosuria, and aminoaciduria in acute tubular necrosis. Arch Pathol 1975; 99: 658-662.
-
(1975)
Arch Pathol
, vol.99
, pp. 658-662
-
-
Carone, F.A.1
Ganote, C.E.2
-
75
-
-
84892388907
-
Sex-specific differences in cognitive functioning among schizophrenic patients
-
Krysta K, Murawiec S, Klasik A, Wiglusz MS, Krupka-Matuszczyk I. Sex-specific differences in cognitive functioning among schizophrenic patients. Psychiatr Danub 2013; 25: S244-S246.
-
(2013)
Psychiatr Danub
, vol.25
, pp. S244-S246
-
-
Krysta, K.1
Murawiec, S.2
Klasik, A.3
Wiglusz, M.S.4
Krupka-Matuszczyk, I.5
-
76
-
-
17044458815
-
Modeling the early course of schizophrenia
-
Hafner H, Maurer K, Loffler W, an der Heiden W, Hambrecht M, Schultze-Lutter F. Modeling the early course of schizophrenia. Schizophr Bull 2003; 29: 325-340.
-
(2003)
Schizophr Bull
, vol.29
, pp. 325-340
-
-
Hafner, H.1
Maurer, K.2
Loffler, W.3
An Der Heiden, W.4
Hambrecht, M.5
Schultze-Lutter, F.6
-
77
-
-
84857082115
-
Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes
-
Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M. Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol 2012; 165: 1543-1555.
-
(2012)
Br J Pharmacol
, vol.165
, pp. 1543-1555
-
-
Tanahashi, S.1
Yamamura, S.2
Nakagawa, M.3
Motomura, E.4
Okada, M.5
-
78
-
-
8744278883
-
Glutamate as a therapeutic target in psychiatric disorders
-
Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004; 9: 979.
-
(2004)
Mol Psychiatry
, vol.9
, pp. 979
-
-
Javitt, D.C.1
|